674791-95-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-3,3-dimethylpiperazine is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of potential drug candidates for various therapeutic applications.
Used in Medicinal Chemistry:
1-Benzyl-3,3-dimethylpiperazine is used as a building block for creating new pharmaceutical compounds, leveraging its properties to enhance the therapeutic potential of medications.
Used in Organic Synthesis:
1-Benzyl-3,3-dimethylpiperazine is used as an important intermediate in the production of various organic compounds, highlighting its versatility and significance in chemical reactions and processes.
Used in Biological Research:
1-Benzyl-3,3-dimethylpiperazine is utilized in biological studies to explore its potential biological activities, which may contribute to the advancement of pharmaceutical applications and drug discovery.

Upstream product

• 674792-01-9 4-benzyl-2,2-dimethylpiperazine-1-carboxylic acid tert-butyl ester 
• 1134542-45-2 1-benzyl-3,3-dimethylpiperazine-2,5-dione 

Relevant academic research and scientific papers

SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

Substituted 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors. The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula, in which R1, R2, R3, R4, R5 and R6 are defined as indicated below. The compounds of the formula 1 are protein kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 -HYDROXYSTEROID DEHYDROGENASE

Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein X is O or S, a broken line and a wavy line represent the presence or the absence of a bond, (i) when a broken line represents the presence of a bond, a wavy line represents the absence of a bond, R2 and R3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, (ii) when a broken line represents the absence of a bond, a wavy line represents the presence of a bond, R1 and R4 are each independently hydrogen, halogen or the like, R2 and R3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, and R5 and R6 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like.

PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS

Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders r